Literature DB >> 24389370

Vaccine-preventable diseases: from paediatric to adult targets.

Susanna Esposito1, Paolo Durando2, Samantha Bosis3, Filippo Ansaldi2, Claudia Tagliabue3, Giancarlo Icardi2.   

Abstract

The morbidity and mortality related to many communicable infectious diseases have significantly decreased in Western countries largely because of the use of antibiotics, and the implementation of well-planned vaccination strategies and national immunisation schedules specifically aimed at infants and children. However, although immunisation has proved to be highly effective for public health, more effort is needed to improve the currently sub-optimal rates of vaccination against various diseases among adults who may be at risk because of their age, medical condition or occupation. The vaccines currently licenced in Western countries are safe, immunogenic and effective against many infectious diseases and their complications, but the availability of newer vaccines or vaccines with new indications, the evolving ecology and epidemiology of many infections, population ageing, and other demographic changes (i.e. the increasing prevalence of chronic comorbidities and immunodeficiencies, mass migration, new working relationships, and widespread international tourism) require changes in the approach to immunisation. There is now a need for appropriate preventive measures for adults and the elderly aimed at protecting people at risk by using every possible catch-up opportunity and recommending specific age-related schedules on the basis of local epidemiology.
Copyright © 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adults; Infectious diseases; Prevention; The elderly; Vaccination; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 24389370     DOI: 10.1016/j.ejim.2013.12.004

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

1.  Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 2: Adult Vaccinations.

Authors:  C Lee Ventola
Journal:  P T       Date:  2016-08

2.  Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 1: Childhood Vaccinations.

Authors:  C Lee Ventola
Journal:  P T       Date:  2016-07

3.  Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges.

Authors:  Sevan Dirmesropian; James G Wood; C Raina MacIntyre; Philippe Beutels; Anthony T Newall
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

Review 4.  Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

Authors:  Susanna Esposito; Paolo Bonanni; Stefania Maggi; Litjan Tan; Filippo Ansaldi; Pier Luigi Lopalco; Ron Dagan; Jean-Pierre Michel; Pierre van Damme; Jacques Gaillat; Roman Prymula; Timo Vesikari; Cristina Mussini; Uwe Frank; Albert Osterhaus; Lucia Pastore Celentano; Marta Rossi; Valentina Guercio; Gaetan Gavazzi
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

5.  Pertussis immunization in healthcare workers working in pediatric settings: Knowledge, Attitudes and Practices (KAP) of Occupational Physicians. Preliminary results from a web-based survey (2017).

Authors:  M RICCò; L Vezzosi; G Gualerzi; N L Bragazzi; F Balzarini
Journal:  J Prev Med Hyg       Date:  2020-04-02

6.  An example of clinical inertia in geriatrics.

Authors:  Tahir Belice; Mustafa Ubay; Fatma O Gozubuyuk; Rasim S Yilmaz; Arif Yuksel
Journal:  J Family Med Prim Care       Date:  2020-11-30

Review 7.  Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion.

Authors:  T Mark Doherty; Giuseppe Del Giudice; Stefania Maggi
Journal:  Ann Med       Date:  2019-04-26       Impact factor: 4.709

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.